The activist investor Engine Capital is lobbying for big changes at Avantor, urging the life science toolmaker to either cut ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...